Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
8 Apr 24
8-K
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
26 Mar 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Gain Therapeutics’ Ceo Matthias Alder Issues Letter to Shareholders and Provides Operational Update
31 Jan 24
8-K
Gain Therapeutics Announces Proposed Public Offering
22 Nov 23
8-K
Termination of a Material Definitive Agreement
17 Nov 23
8-K
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
14 Nov 23
8-K
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
8-K
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
12 May 23
Registration and prospectus
424B3
Prospectus supplement
2 Jan 24
S-1
IPO registration
19 Dec 23
424B5
Prospectus supplement for primary offering
24 Nov 23
424B5
Prospectus supplement for primary offering
20 Nov 23
S-8
Registration of securities for employees
26 May 23
S-8
Registration of securities for employees
15 Jul 22
S-3/A
Shelf registration (amended)
23 May 22
S-3
Shelf registration
18 May 22
S-8
Registration of securities for employees
6 Apr 21
424B4
Prospectus supplement with pricing info
22 Mar 21
Other
EFFECT
Notice of effectiveness
2 Jan 24
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
EFFECT
Notice of effectiveness
2 Jun 22
CORRESP
Correspondence with SEC
31 May 22
UPLOAD
Letter from SEC
20 May 22
EFFECT
Notice of effectiveness
18 Mar 21
CERT
Certification of approval for exchange listing
17 Mar 21
CORRESP
Correspondence with SEC
16 Mar 21
UPLOAD
Letter from SEC
16 Mar 21